The Effect of Serum and Follicle Fluid Melatonin Levels on In-Vitro Fertilization Success Between Polycystic Ovary Syndrome and Unexplained Infertility Patient Groups in In-Vitro Fertilization

Öz

Objective: To investigate the difference in the serum melatonin and follicle fluid melatonin levels at unexplained infertility and polycystic ovary syndrome (PCOS) patients who underwent in-vitro fertilization (IVF) treatment, and to investigate whether the melatonin level affects oocyte quality, embryo number, and clinical pregnancy. Material and Method: Women with unexplained infertility (n=26) and women with the polycystic ovarian syndrome (n=26) who started IVF treatment were included in this prospective trial. The levels of melatonin in the groups’ were tested using the enzyme-linked immunosorbent (ELIZA) method. In addition, the effect of the difference in melatonin levels between the groups on IVF success was investigated. Results: Patients with the polycystic ovarian syndrome had significantly low serum melatonin levels (p=0.018). Melatonin levels in follicular fluid were similar in both groups (p=0.701). Total oocyte, M2 oocyte, PN2 oocyte, grade A embryo, second-day embryo count, and the number of transferred embryos did not differ across the groups (p>0.05). There was no significant relationship between serum and follicular fluid melatonin levels (p>0.05). There was no significant relationship between clinical pregnancy and melatonin level (p>0.05). There was no statistical difference between the groups regarding age, weight, height, and body mass index (p>0.05). Conclusion: In our study, serum melatonin levels were lower in infertile women with polycystic ovary syndrome. This may be due to high melatonin consumption. However, melatonin levels in the serum and follicular fluid had no direct effect on IVF outcomes.

Anahtar Kelimeler

• Unexplained infertility
• Follicular Fluid
• Melatonin
• PCOS

Tüp Bebek Tedavisinde Polikistik Over Sendromu ve Açıklanamayan İnfertilite Hasta Gruplarında Serum ve Folikül Sıvısı Melatonin Düzeylerinin Tüp Bebek Başarısı Üzerine Etkisi

Öz

Amaç: Açıklanamayan infertilite ve tüp bebek tedavisi gören PKOS (Polikistik Over Sendromu) hastalarında serum ve folikül sıvısı melatonin düzeyleri arasındaki farkı araştırmak ve melatonin düzeyinin oosit kalitesi, embriyo sayısı ve klinik gebelik üzerine etkilerini araştırmak. Gereç ve Yöntem: Bu prospektif çalışmaya, açıklanamayan infertilitesi olan kadınlar (n=26) ve polikistik over sendromlu (n=26) tüp bebek tedavisine başlayan kadınlar dahil edildi. Grupların serum ve foliküler sıvısındaki melatonin düzeyleri ELIZA yöntemi kullanılarak test edildi. Ayrıca gruplar arasındaki melatonin düzeyi farklılığının IVF başarısına etkisi araştırıldı. Bulgular: Polikistik over sendromlu hastaların serum melatonin düzeyleri anlamlı düzeyde az idi (p=0.018). Foliküler sıvıdaki melatonin düzeyleri her iki grupta da benzerdi (p=0.701). Toplam oosit, M2 oosit, PN2 oosit, A sınıfı embriyo, ikinci gün embriyo sayısı ve transfer edilen embriyo sayısı açısından gruplar arasında anlamlı fark yoktu (p>0.05). Serum ve foliküler sıvı melatonin düzeyleri arasında anlamlı bir ilişki saptanmadı (p>0.05). Klinik gebelik ile melatonin düzeyi arasında anlamlı bir ilişki bulunmadı (p>0.05). Gruplar arasında yaş, kilo, boy ve vücut kitle indeksi açısından istatistiksel fark yoktu (p>0.05). Sonuç: Çalışmamızda polikistik over sendromlu infertil kadınlarda serum melatonin düzeyleri daha düşüktü. Bunun nedeni yüksek melatonin tüketimi olabilir. Ancak serum ve foliküler sıvıdaki melatonin düzeylerinin IVF sonucuna doğrudan bir etkisinin olmadığı görüldü.

Anahtar Kelimeler

• Açıklanamayan İnfertilite
• Foliküler Sıvı
• Melatonin
• Polikistik Over Sendromu

Kaynakça

1. Luo L, Zeng X, Huang Z, Luo S, Qin L, Li S. Reduced frequency and functional defects of CD4+ CD25 high CD127 low/− regulatory T cells in patients with unexplained recurrent spontaneous abortion. Reprod Biol Endocrinol 2020;18:1-10.
2. Athaullah N, Proctor M, Johnson NP. Oral versus injectable ovulation induction agents for unexplained subfertility. Cochrane Database Syst Rev 2002;2002(3):CD003052.
3. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. JCEM 2005;1929-1935.
4. Brzezinski A, Seibel MM, Lynch H J, Deng MH, Wurtman R J. Melatonin in human preovulatory follicular fluid. JCEM 1987;64(4):865-867.
5. Giannetto A, Fernandes JM, Nagasawa K, et al. Influence of continuous light treatment on expression of stress biomarkers in Atlantic cod. DCI 2014;44(1):30-34.
6. Goud AP, Goud PT, Diamond MP, Gonik B, Abu-Soud HM. Reactive oxygen species and oocyte aging: role of superoxide, hydrogen peroxide, and hypochlorous acid. Rad Biol Med 2008;44(7):1295-1304.
7. Lemos AJJM, Peixoto CA, Teixeira ÁAC, et al. Effect of the combination of metformin hydrochloride and melatonin on oxidative stress before and during pregnancy, and biochemical and histopathological analysis of the livers of rats after treatment for polycystic ovary syndrome. Toxicology and Applied Pharmacology 2014;280(1):159-168.
8. Kang JT, Koo OJ, Kwon DK, et al. Effects of melatonin on in vitro maturation of porcine oocyte and expression of melatonin receptor RNA in cumulus and granulosa cells. JPR 2009;46(1):22-28.

9. Shreeve N, Cagampang F, Sadek K, et al. Poor sleep in PCOS; is melatonin the culprit. Hum Reprod 2013;28(5):1348-1353.
10. Lemos AJJM, Peixoto CA, Teixeira ÁAC, et al. Effect of the combination of metformin hydrochloride and melatonin on oxidative stress before and during pregnancy, and biochemical and histopathological analysis of the livers of rats after treatment for polycystic ovary syndrome. Toxicology and Applied Pharmacology 2014;280(1):159-168.
11. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fert Stert 2003;80(1):123-127.
12. Mauriz JL, Collado PS, Veneroso C, Reiter RJ, González‐Gallego J. A review of the molecular aspects of melatonin’s anti‐inflammatory actions: recent insights and new perspectives. JPR 2013;54(1):1-14.
13. Luboshitzky R, Qupti G, Ishay A, Shen-Orr Z, Futerman B, Linn S. Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome. Fert Stert 2001;76(3):506-510.
14. Pacchiarotti A, Carlomagno G, Antonini G, Pacchiarotti A. Effect of myoinositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecological Endocrinology 2016;32(1):69-73.
15. Reiter RJ, Tan DX, Maldonado MD. Melatonin as an antioxidant: physiology versus pharmacology. JPR 2005;39(2):215-216.
16. Tamura H, Nakamura Y, Korkmaz A, et al. Melatonin and the ovary: physiological and pathophysiological implications. Fert Stert 2009;92(1):328-343.
17. Jain P, Jain M, Haldar C, Singh TB, Jain S. Melatonin and its correlation with testosterone in polycystic ovarian syndrome. Journal of Human Reproductive Sciences 2013;6(4):253-258.
18. Tamura H, Takasaki A, Taketani T, et al. The role of melatonin as an antioxidant in the follicle. Journal of Ovarian Research 2012;5:1-9
19. Tamura H, Takasaki A, Miwa I, et al. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. JPR 2008;44(3):280-287.
20. Nakamura Y, Tamura H, Takayama H, Kato H. Increased endogenous level of melatonin in preovulatory human follicles does not directly influence progesterone production. Fert Stert 2003;80(4):1012-1016.
21. Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. CMLS 2014;71:2997-3025.
22. Kim MK, Park EA, Kim HJ, et al. Does supplementation of in-vitro culture medium with melatonin improve IVF outcome in PCOS?. RBMO 2013;26(1):22-29.
23. Brzezinski A, Seibel MM, Lynch HJ, Deng MH, Wurtman RJ. Melatonin in human preovulatory follicular fluid. JCEM 1987;64(4):865-867.
24. Dumont A, Robin G, Catteau-Jonard S, Dewailly D. Role of AntiMüllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reprod Bio End 2015;13:1-10.
25. Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod bio online 2016; 33(1):15-28.
26. Fleming R, Coutts JR. 11 LHRH analogues for ovulation induction, with particular reference to polycystic ovary syndrome. Baillière’s Clin Obs Gyn 1988;677-687.
27. Gougeon A, Ecochard R, Thalabard JC. Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women. Bio of Reprod 1994;653-663.
28. Hull M, Joyce D, Turner G, Wardle P. Undergraduate Obstetrics & Gynaecology. Acta Obst Gyn Scandinavica 1997;76(8):809.
29. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Inter J of Obesity 2002; 26(7):883-896.